Search results
Earnings call: Avadel Pharmaceuticals posts strong Q1 2024 results By Investing.com
Investing.com· 5 days agoThe company has seen significant growth in patient enrollment and therapy initiation for their...
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
GuruFocus.com via Yahoo Finance· 7 days agoCompany Overview Avadel Pharmaceuticals focuses on developing and commercializing unique...
Headache Behind Eyes
Verywell Health via Yahoo News· 15 hours ago... weight, obesity Family history of headaches or headache disorders Having a sleep disorder, such as insomnia or narcolepsy Working with screens (for...
Takeda profit slumps by half as Japanese drugmaker rebuilds pipeline
KFGO· 6 days agoTOKYO (Reuters) - Japan's Takeda Pharmaceutical said full-year earnings slumped by more than half as...
RFK Jr. Explains Why His Voice Sounds Hoarse
MedPage Today· 6 days agoWelcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical...
Wellbutrin vs Adderall: Important Differences You Should Know
MediaFeed via AOL· 7 days agoAnxiety and depression are two common mental conditions — it’s estimated that about 40 million...
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
InvestorPlace· 4 days agoThe biotech sector holds some of the most promising and popular stocks on the market. With the...
Prediction: These 2 Growth Stocks Could Triple By 2030
Motley Fool via Yahoo Finance· 4 days agoHowever, Axsome's innovative days aren't behind it, which may allow the company to continue...
Groundbreaking Data Collection Platform opens to accelerate research in Central Disorders of...
NBC 10 - FOX 14 Monroe· 13 hours agoSleep Consortium, in partnership with leading sleep-related patient advocacy organizations, the global patient community, and key industry stakeholders, is thrilled to announce the launch of ...
Citigroup Lowers Axsome Therapeutics (NASDAQ:AXSM) Price Target to $125.00
ETF DAILY NEWS· 6 days agoAxsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective reduced by Citigroup from $127.00 to $125.00 in a research note issued to investors on Tuesday, Benzinga reports.
